Locoregional risk assessment after neoadjuvant chemotherapy in patients with primary breast cancer: clinical utility of the CPS + EG score

Purpose: Locoregional control is a prerequisite to cure primary breast cancer but the prediction of locoregional recurrence to guide further local therapy following neoadjuvant chemotherapy remains a challenge. The CPS + EG score was designed to predict distant recurrences. Here we examine its abili...

Full description

Saved in:
Bibliographic Details
Main Authors: Michel, Laura L. (Author) , Sommer, Laura (Author) , González Silos, Rosa (Author) , Lorenzo Bermejo, Justo (Author) , Au, Alexandra von (Author) , Seitz, Julia (Author) , Hennigs, André (Author) , Smetanay, Katharina (Author) , Golatta, Michael (Author) , Heil, Jörg (Author) , Schütz, Florian (Author) , Sohn, Christof (Author) , Schneeweiss, Andreas (Author) , Marmé, Frederik (Author)
Format: Article (Journal)
Language:English
Published: 24 June 2019
In: Breast cancer research and treatment
Year: 2019, Volume: 177, Issue: 2, Pages: 437-446
ISSN:1573-7217
DOI:10.1007/s10549-019-05314-9
Online Access:Verlag, Volltext: https://doi.org/10.1007/s10549-019-05314-9
Get full text
Author Notes:Laura L. Michel, Laura Sommer, Rosa González Silos, Justo Lorenzo Bermejo, Alexandra von Au, Julia Seitz, André Hennigs, Katharina Smetanay, Michael Golatta, Jörg Heil, Florian Schütz, Christof Sohn, Andreas Schneeweiss, Frederik Marmé

MARC

LEADER 00000caa a2200000 c 4500
001 1672441587
003 DE-627
005 20230426122747.0
007 cr uuu---uuuuu
008 190829s2019 xx |||||o 00| ||eng c
024 7 |a 10.1007/s10549-019-05314-9  |2 doi 
035 |a (DE-627)1672441587 
035 |a (DE-599)KXP1672441587 
035 |a (OCoLC)1341238697 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Michel, Laura L.  |d 1984-  |e VerfasserIn  |0 (DE-588)1018124888  |0 (DE-627)680395857  |0 (DE-576)355064529  |4 aut 
245 1 0 |a Locoregional risk assessment after neoadjuvant chemotherapy in patients with primary breast cancer  |b clinical utility of the CPS + EG score  |c Laura L. Michel, Laura Sommer, Rosa González Silos, Justo Lorenzo Bermejo, Alexandra von Au, Julia Seitz, André Hennigs, Katharina Smetanay, Michael Golatta, Jörg Heil, Florian Schütz, Christof Sohn, Andreas Schneeweiss, Frederik Marmé 
264 1 |c 24 June 2019 
300 |a 10 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 29.08.2019 
520 |a Purpose: Locoregional control is a prerequisite to cure primary breast cancer but the prediction of locoregional recurrence to guide further local therapy following neoadjuvant chemotherapy remains a challenge. The CPS + EG score was designed to predict distant recurrences. Here we examine its ability to predict both not only distant but also locoregional recurrences with respect to accuracy and clinical applicability. Methods: Clinical data from 432 patients with primary breast cancer treated with neoadjuvant chemotherapy between 2003 and 2011 were prospectively collected. Using the Kaplan-Meier method we analyzed the risk of local and distant recurrences according to individual CPS + EG scores, stratified by type of surgery. Possible confounding of the relationship between recurrence risk and CPS + EG score by established risk factors was accounted for in multiple survival regression models. Additionally, we analyzed the performance of the CPS + EG score to predict isolated locoregional recurrence by censoring patients with prior or simultaneous distant metastases. Results: 5-year locoregional recurrence-free survival was 90%, and 5-year distant metastases-free survival was 82%. The CPS + EG score stratified patients into six prognostic groups with distinct 5-year locoregional recurrence-free survival, ranging from 100 to 41% (p = 0.02) and 5-year distant metastases-free survival, ranging from 96 to 35% (p < 0.0001). 8 patients (17%) with CPS + EG scores ≥ 4 experienced locoregional recurrence—5 of them presented with simultaneous distant disease. Conclusion: The CPS + EG score, originally designed to predict distant relapse, is also valuable for assessing local recurrence risks. Our data demonstrate that distant and locoregional recurrence risks are closely related. As prognosis of patients with high risk of locoregional failure based on CPS + EG is dominated by distant recurrences, escalating local therapies may have limited impact on overall prognosis. 
650 4 |a CPS + EG score 
650 4 |a Neoadjuvant chemotherapy 
650 4 |a Primary breast cancer 
650 4 |a Prognostic index 
700 1 |a Sommer, Laura  |d 1991-  |e VerfasserIn  |0 (DE-588)1188894595  |0 (DE-627)1667756141  |4 aut 
700 1 |a González Silos, Rosa  |e VerfasserIn  |0 (DE-588)1121144195  |0 (DE-627)874011930  |0 (DE-576)480745471  |4 aut 
700 1 |a Lorenzo Bermejo, Justo  |d 1972-  |e VerfasserIn  |0 (DE-588)124754619  |0 (DE-627)706705572  |0 (DE-576)294483632  |4 aut 
700 1 |a Au, Alexandra von  |d 1985-  |e VerfasserIn  |0 (DE-588)1022333909  |0 (DE-627)716953366  |0 (DE-576)362850666  |4 aut 
700 1 |a Seitz, Julia  |d 1981-  |e VerfasserIn  |0 (DE-588)1127256173  |0 (DE-627)88170623X  |0 (DE-576)485156679  |4 aut 
700 1 |a Hennigs, André  |e VerfasserIn  |0 (DE-588)1077795238  |0 (DE-627)837512395  |0 (DE-576)446682780  |4 aut 
700 1 |a Smetanay, Katharina  |d 1982-  |e VerfasserIn  |0 (DE-588)140122036  |0 (DE-627)616034857  |0 (DE-576)314686452  |4 aut 
700 1 |a Golatta, Michael  |d 1974-  |e VerfasserIn  |0 (DE-588)132350386  |0 (DE-627)521535727  |0 (DE-576)299091392  |4 aut 
700 1 |a Heil, Jörg  |d 1978-  |e VerfasserIn  |0 (DE-588)132580187  |0 (DE-627)52396160X  |0 (DE-576)299238679  |4 aut 
700 1 |a Schütz, Florian  |d 1972-  |e VerfasserIn  |0 (DE-588)12303387X  |0 (DE-627)082307229  |0 (DE-576)293528810  |4 aut 
700 1 |a Sohn, Christof  |d 1961-  |e VerfasserIn  |0 (DE-588)131349287  |0 (DE-627)507642902  |0 (DE-576)298422255  |4 aut 
700 1 |a Schneeweiss, Andreas  |d 1961-  |e VerfasserIn  |0 (DE-588)109972554  |0 (DE-627)632849630  |0 (DE-576)327251859  |4 aut 
700 1 |a Marmé, Frederik  |d 1974-  |e VerfasserIn  |0 (DE-588)132561972  |0 (DE-627)52394893X  |0 (DE-576)299226549  |4 aut 
773 0 8 |i Enthalten in  |t Breast cancer research and treatment  |d Dordrecht [u.a.] : Springer Science + Business Media B.V., 1981  |g 177(2019), 2, Seite 437-446  |h Online-Ressource  |w (DE-627)320433722  |w (DE-600)2004077-5  |w (DE-576)104194162  |x 1573-7217  |7 nnas  |a Locoregional risk assessment after neoadjuvant chemotherapy in patients with primary breast cancer clinical utility of the CPS + EG score 
773 1 8 |g volume:177  |g year:2019  |g number:2  |g pages:437-446  |g extent:10  |a Locoregional risk assessment after neoadjuvant chemotherapy in patients with primary breast cancer clinical utility of the CPS + EG score 
856 4 0 |u https://doi.org/10.1007/s10549-019-05314-9  |x Verlag  |x Resolving-System  |3 Volltext 
951 |a AR 
992 |a 20190829 
993 |a Article 
994 |a 2019 
998 |g 132561972  |a Marmé, Frederik  |m 132561972:Marmé, Frederik  |d 910000  |d 910400  |e 910000PM132561972  |e 910400PM132561972  |k 0/910000/  |k 1/910000/910400/  |p 14  |y j 
998 |g 109972554  |a Schneeweiss, Andreas  |m 109972554:Schneeweiss, Andreas  |d 910000  |d 910400  |e 910000PS109972554  |e 910400PS109972554  |k 0/910000/  |k 1/910000/910400/  |p 13 
998 |g 131349287  |a Sohn, Christof  |m 131349287:Sohn, Christof  |d 910000  |d 910400  |e 910000PS131349287  |e 910400PS131349287  |k 0/910000/  |k 1/910000/910400/  |p 12 
998 |g 12303387X  |a Schütz, Florian  |m 12303387X:Schütz, Florian  |d 910000  |d 910400  |d 50000  |e 910000PS12303387X  |e 910400PS12303387X  |e 50000PS12303387X  |k 0/910000/  |k 1/910000/910400/  |k 0/50000/  |p 11 
998 |g 132580187  |a Heil, Jörg  |m 132580187:Heil, Jörg  |d 910000  |d 910400  |e 910000PH132580187  |e 910400PH132580187  |k 0/910000/  |k 1/910000/910400/  |p 10 
998 |g 132350386  |a Golatta, Michael  |m 132350386:Golatta, Michael  |d 910000  |d 910400  |e 910000PG132350386  |e 910400PG132350386  |k 0/910000/  |k 1/910000/910400/  |p 9 
998 |g 140122036  |a Smetanay, Katharina  |m 140122036:Smetanay, Katharina  |d 910000  |d 910400  |e 910000PS140122036  |e 910400PS140122036  |k 0/910000/  |k 1/910000/910400/  |p 8 
998 |g 1077795238  |a Hennigs, André  |m 1077795238:Hennigs, André  |d 910000  |d 910400  |e 910000PH1077795238  |e 910400PH1077795238  |k 0/910000/  |k 1/910000/910400/  |p 7 
998 |g 1127256173  |a Seitz, Julia  |m 1127256173:Seitz, Julia  |d 910000  |d 910400  |e 910000PS1127256173  |e 910400PS1127256173  |k 0/910000/  |k 1/910000/910400/  |p 6 
998 |g 1022333909  |a Au, Alexandra von  |m 1022333909:Au, Alexandra von  |d 910000  |d 910400  |e 910000PA1022333909  |e 910400PA1022333909  |k 0/910000/  |k 1/910000/910400/  |p 5 
998 |g 124754619  |a Lorenzo Bermejo, Justo  |m 124754619:Lorenzo Bermejo, Justo  |d 910000  |d 999701  |e 910000PL124754619  |e 999701PL124754619  |k 0/910000/  |k 1/910000/999701/  |p 4 
998 |g 1121144195  |a González Silos, Rosa  |m 1121144195:González Silos, Rosa  |d 910000  |d 999701  |e 910000PG1121144195  |e 999701PG1121144195  |k 0/910000/  |k 1/910000/999701/  |p 3 
998 |g 1188894595  |a Sommer, Laura  |m 1188894595:Sommer, Laura  |d 910000  |d 910400  |e 910000PS1188894595  |e 910400PS1188894595  |k 0/910000/  |k 1/910000/910400/  |p 2 
998 |g 1018124888  |a Michel, Laura L.  |m 1018124888:Michel, Laura L.  |d 910000  |d 910100  |e 910000PM1018124888  |e 910100PM1018124888  |k 0/910000/  |k 1/910000/910100/  |p 1  |x j 
999 |a KXP-PPN1672441587  |e 350965210X 
BIB |a Y 
SER |a journal 
JSO |a {"title":[{"title_sort":"Locoregional risk assessment after neoadjuvant chemotherapy in patients with primary breast cancer","subtitle":"clinical utility of the CPS + EG score","title":"Locoregional risk assessment after neoadjuvant chemotherapy in patients with primary breast cancer"}],"person":[{"family":"Michel","given":"Laura L.","display":"Michel, Laura L.","role":"aut"},{"family":"Sommer","display":"Sommer, Laura","given":"Laura","role":"aut"},{"given":"Rosa","display":"González Silos, Rosa","role":"aut","family":"González Silos"},{"family":"Lorenzo Bermejo","given":"Justo","display":"Lorenzo Bermejo, Justo","role":"aut"},{"family":"Au","given":"Alexandra von","display":"Au, Alexandra von","role":"aut"},{"family":"Seitz","given":"Julia","display":"Seitz, Julia","role":"aut"},{"family":"Hennigs","given":"André","display":"Hennigs, André","role":"aut"},{"role":"aut","given":"Katharina","display":"Smetanay, Katharina","family":"Smetanay"},{"role":"aut","given":"Michael","display":"Golatta, Michael","family":"Golatta"},{"family":"Heil","role":"aut","display":"Heil, Jörg","given":"Jörg"},{"role":"aut","display":"Schütz, Florian","given":"Florian","family":"Schütz"},{"family":"Sohn","role":"aut","given":"Christof","display":"Sohn, Christof"},{"display":"Schneeweiss, Andreas","given":"Andreas","role":"aut","family":"Schneeweiss"},{"family":"Marmé","role":"aut","display":"Marmé, Frederik","given":"Frederik"}],"physDesc":[{"extent":"10 S."}],"id":{"doi":["10.1007/s10549-019-05314-9"],"eki":["1672441587"]},"language":["eng"],"name":{"displayForm":["Laura L. Michel, Laura Sommer, Rosa González Silos, Justo Lorenzo Bermejo, Alexandra von Au, Julia Seitz, André Hennigs, Katharina Smetanay, Michael Golatta, Jörg Heil, Florian Schütz, Christof Sohn, Andreas Schneeweiss, Frederik Marmé"]},"type":{"media":"Online-Ressource","bibl":"article-journal"},"recId":"1672441587","relHost":[{"origin":[{"dateIssuedDisp":"1981-","publisher":"Springer Science + Business Media B.V. ; Kluwer","dateIssuedKey":"1981","publisherPlace":"Dordrecht [u.a.] ; Dordrecht [u.a.]"}],"note":["Gesehen am 02.12.05","Fortsetzung der Druck-Ausgabe"],"pubHistory":["1.1981 -"],"recId":"320433722","language":["eng"],"id":{"eki":["320433722"],"zdb":["2004077-5"],"issn":["1573-7217"]},"type":{"bibl":"periodical","media":"Online-Ressource"},"part":{"text":"177(2019), 2, Seite 437-446","year":"2019","pages":"437-446","issue":"2","volume":"177","extent":"10"},"title":[{"title_sort":"Breast cancer research and treatment","title":"Breast cancer research and treatment"}],"disp":"Locoregional risk assessment after neoadjuvant chemotherapy in patients with primary breast cancer clinical utility of the CPS + EG scoreBreast cancer research and treatment","physDesc":[{"extent":"Online-Ressource"}]}],"origin":[{"dateIssuedDisp":"24 June 2019","dateIssuedKey":"2019"}],"note":["Gesehen am 29.08.2019"]} 
SRT |a MICHELLAURLOCOREGION2420